Nat Biomed Engine: Heavy! Chinese scientists have developed a new precision-treated leukemia vaccine

October 19, 2020 // -- In a recent study published in the international journal Nature Biomedical Engineering, scientists from the Institute of Process Engineering of the Chinese Academy of Sciences and the Pearl River Hospital of Southern Medical University are expected to develop a precision-based therapeutic leukemia vaccine.
researchers say exploring new leukemia antigens and using FDA-approved talent to build appropriate transportation administration systems is an important strategy for developing leukemia vaccines for clinical use.
Photo Source: WEI Wei Researchers have developed a therapeutic vaccine against leukemia that uses a self-healing polylectic acid microcapsules to include a new table peptide and PD-1 antibody, although it is now possible to treat leukemia with a vaccine, but its treatment is still far from 'Our clinical results show that EPS8 and PD-1/PD-L1 in leukemia patients have higher levels of expression in the body and may be used as a new type of leukemia antigen and checkpoint target to help develop a new leukemia vaccine, respectively,' said researcher Li Yuhua.
In this new vaccine, surface peptides and PD-1 antibodies can be simply, gently and effectively reproduced into poly lactic acid microcapsules, while facilitating this process through the special self-healing properties of microcapsules.
When a single inoculation was performed, the deposition and degradation of microcapsules at the local injection site led to the recruitment of active antigen delivery cells and the continued release of two "goods", and the researchers observed a significant improvement in the activity of special cytotoxic T lymphocytes.
The researchers then confirmed the effectiveness of the new vaccine using a variety of surface peptides in different models, including mouse leukemia models, human-derived cell line-derived leukemia allogeneic grafts (CDX) and leukemia foreign graft models derived from the patient's body.
This microcapsules-based ingredient has outperformed ISA adjeers( a commercialized admins) in all leukemia therapeutic models, and has also demonstrated the prospects and hopes of a new microcapsules-based vaccine to be used clinically against a variety of leukemia antigens.
The researchers concluded that the new microcapsules vaccine may show great potential in clinical trials based on FDA-approved polylectic acid materials, ease of preparation of vaccine formulations, diversification of vaccine ingredients, and good therapeutic results.
() Original source: Xiaoling Xie, Yuxing Hu, Tong Ye, et al. Therapeutic ingest leukemia via the sustained release of co-encapsulated anti-PD-1 and a leukemia-associated antigen. Nature Biomedical Engineering (2020). DOI:10.1038/s41551-020-00624-6